398 results on '"Pettengell R"'
Search Results
2. Relaxation versus exercise for improved quality of life in lymphoma survivors—a randomised controlled trial
3. Lymphoma survivors’ experience of participation in a home-based intervention post-chemotherapy
4. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial
5. AVELUMAB MONOTHERAPY FOLLOWED BY A PET ADAPTED CHEMOTHERAPY APPROACH IN THE FIRST LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA: INITIAL RESULTS FROM THE AVENUE WINDOW STUDY
6. Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)
7. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel
8. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
9. The addition of rituximab to CODOX-M & IVAC in first line therapy of poor risk Burkitt lymphoma (IPI 3–5) yields an excellent outcome: A phase 2 UK NCRI/Bloodwise Trial (LLR 04058): 209
10. Front line therapy with R-CODOX-M & R-IVAC in poor risk diffuse large B cell lymphoma (IPI 3–5) yields a good outcome without transplantation: A phase 2 UK NCRI/Bloodwise Trial: 210
11. The role of HOX genes in normal hematopoiesis and acute leukemia
12. The impact of follicular lymphoma on health-related quality of life
13. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours
14. Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours
15. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation
16. Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
17. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology
18. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
19. Relaxation versus exercise for improved quality of life in lymphoma survivors—a randomised controlled trial
20. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma
21. 6-year follow-up of the mint study suggests a role for radiotherapy to bulky disease: V648
22. Rituximab added to CHOP-like chemotherapy improves the outcome of primary mediastinal large B-cell lymphoma (PMBCL) to the same extent as other diffuse large B-cell lymphoma (DLBCL): a subgroup analysis of MabThera International (MInT) Group: V300 - Best Abstract
23. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
24. Thrombopoietin, flt3-ligand and c-kit-ligand modulate HOX gene expression in expanding cord blood CD133+ cells
25. Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF
26. CONFOCAL LASER SCANNING COMPARISON OF AC133 AND CD34 SURFACE ANTIGENS.
27. INTRACELLULAR CD34 ANALYSIS OF AC133+ CELL SUBSETS.
28. B-cell lymphoma developing in a patient on cyclosporin for recalcitrant psoriasis
29. COMPARISON OF OUTCOMES BETWEEN PATIENTS WITH MYC REARRANGED DLBCL AND DOUBLE/ TRIPLE HIT HIGH-GRADE B CELL LYMPHOMA: A PAN-LONDON RETROSPECTIVE REVIEW
30. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC
31. Relaxation and Exercise in Lymphoma Survivors (REIL Study): A Randomised Clinical Trial Protocol
32. MYCOSIS FUNGOIDES TRANSFORMING INTO CD30 POSITIVE LYMPHOMA, WITH B CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
33. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation
34. HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE III GALLIUM STUDY OF OBINUTUZUMAB-BASED AND RITUXIMAB-BASED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED INDOLENT NON-HODGKIN LYMPHOMA
35. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines
36. Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
37. Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation
38. Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma
39. A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy
40. Multiparametric analysis of immature cell populations in umbilical cord blood and bone marrow
41. DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL
42. Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma
43. Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)
44. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
45. The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice
46. Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study
47. Anemia and darbepoetin alfa administration in patients treated with CHOP+/-R Chemotherapy : Results from an observational study of patients with Non-Hodgkin Lymphoma
48. Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)
49. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
50. 942TiP - Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.